By Joseph Walker
A federal court has issued a preliminary injunction that bars
Medtronic Inc. from selling its recently approved CoreValve product
to most new customers in the U.S., a setback for the medical-device
maker in its heated battle with Edwards Lifesciences Corp. for
sales in the growing market for minimally invasive heart
valves.
The ruling was made as part of a patent dispute between the
companies. Chief Judge Gregory M. Sleet, of the Federal District
Court of Delaware, ruled Friday that Edwards Lifesciences had "more
than demonstrated a likelihood of success" that it would prevail in
its claims that its patents are infringed by Medtronic's CoreValve
product.
The court ordered that the injunction go into effect in seven
business days. Medtronic said it would appeal the ruling, and
request the injunction be delayed until the appeals court decides
whether the injunction was properly issued.
Judge Sleet ruled that Medtronic be permitted to continue
selling the CoreValve to patients who cannot be implanted with
Edwards Lifesciences' devices. Judge Sleet said he was convinced
the CoreValve "is a safer device" and produces "better outcomes
with a lower risk of death," but that patients' needs had to be
balanced by the public interest in enforcing patent rights.
Medtronic's CoreValve, an artificial aortic heart valve that is
implanted with a catheter instead of through open-heart surgery,
was approved by the U.S. Food and Drug Administration in January.
Medtronic is seeking to gain market share from Edwards
Lifesciences, whose Sapien aortic valve was until recently the only
FDA-approved catheter valve in the U.S. The Sapien was first
cleared by regulators in 2011.
The valves are a growth area for medical-device companies, which
have suffered from slower sales in core businesses including
pacemakers and implanted defibrillators. Edwards Lifesciences has
projected its Sapien valves will reach world-wide sales this year
of $700 million to $820 million.
Judge Sleet said Friday Edwards Lifesciences was likely to
prevail in the patent dispute since it had won an earlier patent
case against Medtronic, and that Edwards would "suffer a loss of
sales and market share" if Medtronic were permitted to continue
selling CoreValve in the U.S.
Write to Joseph Walker at joseph.walker@wsj.com
Access Investor Kit for Edwards Lifesciences Corp.
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US28176E1082
Access Investor Kit for Medtronic, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US5850551061
Subscribe to WSJ: http://online.wsj.com?mod=djnwires